Physics in Medicine & Biology

Spectral computed tomography (CT) is a burgeoning quantitative imaging technique with applications in oncologic diagnostics, prognostic prediction, tissue perfusion studies, and treatment follow-up. While normalized iodine concentration values have been correlated with microenvironmental biophysical changes, obtaining accurate iodine concentrations, particularly at low concentrations remains difficult due to varying spectral CT instrumentation performance. Hybrid spectral CT systems, combining multiple spectral CT instrumentation techniques, address these quantitation insufficiencies by increasing spectral separation but have not been evaluated on a clinically analogous platform. We validate a hybrid spectral CT system, comprised of clinical-grade components, acquiring four distinct effective spectra and applying efficient noise-reducing weighting schemes to compare iodine noise and bias against conventional kVp-Switching (kVp-S). Two tube current levels (50, 350 mA) and three duty cycle ratios (33/67, 50/50, 75/25) were implemented to elucidate radiation dose exposure and kVp-S parameterization impact. A standard quality assurance (QA) and patient-derived, abdominal IodinePrint phantom were scanned on the system. The average absolute bias in iodine density images of the QA phantom was comparable across acquisition techniques, below 0.5 mg/mL, while quantitative noise improved by 22% using noise-optimized weighting schemes. In the IodinePrint phantom aorta and pancreas structures, the noise-optimized weighting scheme increased signal-to-noise ratio (SNR) by 1.3x compared to kVp-S alone. These results highlight the increased precision of hybrid, multi-channel spectral CT systems and motivate CT designs that enable robust CT biomarker development.

Background. Roughly, half of new type 1 diabetes (T1D) diagnoses occur in individuals under 18 years old and represent a more aggressive destruction of beta cell mass (BCM). [11C]-(+)-PHNO positron emission tomography (PET) imaging is used to assess BCM, but current pancreas PET imaging protocols are limited to adults. Previously published full count data from six healthy controls and five T1Ds (6M/5F; 22 to 53 years old) were used for retrospective analysis. Dynamic [11C]-(+)-PHNO PET/CT scans were acquired and reconstructed using full-count list-mode data. For the current comparison to full count data, 50%, 25% and 10% down-sampled count data were re-reconstructed. Pancreas and spleen (reference region) time-activity-curves (TACs) were assessed, and volume of distribution (VT, mL/cm3) was estimated using the reversible 1-tissue compartment model (1TC) with tmax of 30 min for all count levels. Pancreas and Spleen VT estimates (1TC; tmax= 30 min) were used to calculate non-displaceable binding potential (BPND) and were then correlated to semi-quantitative methods of standardized uptake value ratio (SUVR-1) (20-30 min; ref: spleen) to examine simplified methods using simulated low dose protocols. Finally, we performed dosimetry in adult, adolescent and pediatric phantoms to assess radiation dose for simulated low-dose protocols. Results. Qualitatively, increasing noise can be visualized at successive reduced-count levels images, compared to full-count images. Despite progressively increasing noise in reduced-count images, TACs at each reduced-count level remained similar to full-count TACs in both HC and individuals with T1D. Quantitatively, 1TC VT estimates were similar for all reduced count levels and range of tmax values, compared to full-count (all R2[≥]0.99). Pancreas SUVR-1 (20-30 min) and pancreas BPND (tmax = 30; ref: spleen) were highly correlated for all count levels (all R2[≥]0.80). All age groups were under both the yearly occupational and research scan radiation dose limits when examining mean effective dose equivalent with reduced (1/10th) injected dose protocols. Conclusion. Low-count reconstructed data and simplified reference region approaches provide accurate quantification compared to full-count reconstructions. These results provide evidence that it is possible to perform accurate quantification using simulated low dose protocols to quantify BCM for use in individuals with T1D under 18 years old.

Purpose: To determine the feasibility of a 2-minute multi-echo UTE (mecho-UTE) for CT-like bone-weighted contrast and T2* quantification of tissues with short T2/T2*. Methods: Mecho-UTE data acquired from four patients and five healthy subjects were used to assess image quality of the CT-like contrast. All data were reconstructed using conventional gridding (GRID+CONV) and compared with those reconstructed using conjugate gradient SENSE combined with deep learning-based denoising (CG+DLR). Image resolution and sharpness of the CT-like images were assessed using the full width at half maximum (FWHM) and relative edge sharpness (RESH), respectively. Calimetrix UTE-T2* phantom was used to assess the accuracy of T2* quantification of the mecho-UTE sequence. Results: Two-minute mecho-UTE with CG+DLR has similar accuracy (0.37 {+/-} 0.27 vs. 0.67 {+/-} 0.54 ms, p=0.20) and better precision (0.28 {+/-} 0.16 vs. 1.23 {+/-} 0.29 ms, p<0.001) compared to the 5-minute mecho-UTE with GRID+CONV. The 2-minute mecho-UTE with CG+DLR has higher resolution and sharpness compared to the 5-minute scan with GRID+CONV. Conclusion: It is feasible to achieve simultaneous CT-like contrast and T2* quantification of short-T2 tissues in two minutes. When appropriately used, it may simplify logistics, reduce costs, and eliminate radiation exposure risks.

Purpose: Respiratory motion remains a major source of quantitative bias in PET and becomes increasingly relevant for high-sensitivity long axial field-of-view (LAFOV) PET/CT. Although numerous respiratory motion correction (MoCo) methods have been proposed, their quantitative accuracy cannot be established clinically because a patient-specific motion-free reference is fundamentally unavailable in vivo. This study combined clinical PET imaging with a digital twin, a realistic representation of both the PET/CT system and the patient, to objectively validate respiratory MoCo against a corresponding motion-free reference. Methods: Twenty patients (10 [18F]FDG with predominantly pulmonary lesions and 10 [18F]SiFAlin-TATE with predominantly hepatic lesions; total 135 lesions) were analyzed. The digital twin combined a validated LAFOV PET/CT simulation model with an anatomically realistic phantom containing 14 lung and liver lesions, two patient-derived respiratory patterns, and respiratory motion amplitudes of 2 and 3 cm, generating patient-like datasets with corresponding motion-free references. Data-driven and image-based MoCo were evaluated using lesion morphology, SUVmean, SUVmax, and metabolic tumor volume (MTV). Results: In patients, data-driven MoCo produced larger SUVmean increases than image-based MoCo for liver (48.1{+/-}18.9% vs. 17.0 {+/-} 12.0%; p<0.01), lower-lung (32.5{+/-}21.2% vs. 16.3{+/-}15.6%, p=0.06), and upper-lung lesions (28.4{+/-}32.0% vs. 10.4 {+/-} 17.2%; p<0.01), with similar findings for SUVmax and larger MTV reductions. Simulation revealed marked motion-induced SUVmean underestimation before correction, particularly in liver (-31.2{+/-}6.8%) and lower lung (-15.5{+/-}13.9%). Relative to the motion-free reference, data-driven MoCo most accurately recovered hepatic uptake (4.3{+/-}11.7% vs. -10.0 {+/-} 9.2%; p=0.01) but overestimated pulmonary uptake (lower lung: 19.8{+/-}16.3% vs. -1.6 {+/-} 10.2%; p=0.02). SUVmax showed the same regional behavior, whereas image-based MoCo yielded MTV estimates closer to the reference. Quantitative recovery was largely independent of respiratory pattern, while larger motion amplitudes mainly affected image-based MoCo. Conclusion: Combining clinical PET with a realistic digital twin and corresponding motion-free ground truth enabled objective validation of respiratory MoCo beyond conventional clinical evaluation. Larger correction-induced quantitative changes should not be equated with greater quantitative accuracy. Instead, MoCo performance was region- and metric-dependent, highlighting the value of ground-truth-based validation for developing and benchmarking respiratory motion correction and quantitative PET on LAFOV PET/CT systems.

Dynamic positron emission tomography (PET) with long axial field-of-view (LAFOV) scanners enables multi-organ imaging and kinetic quantification beyond static (late-phase) imaging; however, the long times typically required for dynamic acquisitions remain clinically impractical. This study evaluates a deep learning (DL) framework to enable abbreviated dynamic PET acquisitions, comparing single-time-window (STW, early dynamic data only) and dual-time-window (DTW, early dynamic data plus a late 5-min static frame) protocols with early dynamic scan durations of 5-30 min and dose levels ranging from 360 MBq to 18 MBq. Seventeen 60-min dynamic [18F]FDG datasets were first motion-corrected using a staggered FALCON pipeline and then used to train and test a spatiotemporal DL model for autoregressive frame prediction. Performance was assessed across the full quantitative workflow, from DL-predicted frames and time-activity curves to organ-based kinetic modeling and voxel-wise parametric imaging in multiple tissues and two patient cohorts. DTW protocols consistently outperformed STW, better preserving late-phase kinetics. For a 15-min early dynamic scan, adding a late 5-min scan reduced mean absolute Ki difference from 23% (STW) to 17% (DTW) in the liver and from 26% to 15% in the thalamus. DTW + DL further reduced errors to [&le;]10% in the liver, thalamus, and breast lesion, and 16% in muscle. Our recommended protocol, 15-min early dynamic scan plus a 5-min late scan with DL, remained robust to up to a 5-fold dose reduction (~74 MBq). Overall, these findings support DL-enabled abbreviated, low-dose dynamic LAFOV PET as a clinically feasible approach for accurate kinetic quantification

Background. Accurate delineation of the gross tumour volume (GTV) - primary tumour (GTVp) and nodal disease (GTVn) - on FDG-PET/CT is a critical step of head and neck radiotherapy planning. Comparisons between lightweight custom networks and the auto-configured nnU-Net v2 are usually reported as end-to-end pipelines, conflating the contribution of the network with that of the inference-time post-processing applied on top of it. We separated the two. Methods. MiniUNet3D (custom 3D U-Net, 18.3 M parameters) and nnU-Net v2 (3d_fullres, 88.2 M parameters) were trained on the same 578 FDG-PET/CT cases (85/15 author-defined split of the HECKTOR 2025 Task 1 set, 8 centres) and evaluated on the same internal cohort. Three arms were compared pairwise: MiniUNet3D raw output at a fixed 0.5 threshold, MiniUNet3D with a locked adaptive post-processing pipeline, and nnU-Net v2. Comparisons used paired Wilcoxon tests with bootstrap confidence intervals, Bonferroni and Benjamini-Hochberg correction, and Cohen's d; catastrophic failure (Dice < 0.01) was compared with an exact McNemar test. Cases with an empty reference for a given target were excluded from that target's analysis (n = 98 GTVp, n = 93 GTVn). Results. With post-processing matched off, nnU-Net v2 was superior: median GTVp Dice 0.799 versus 0.592 (mean difference -0.244, 95 % CI -0.300 to -0.191; d = -0.88) and GTVn 0.774 versus 0.598 (d = -0.82). Post-processing raised MiniUNet3D to 0.800 (GTVp) and 0.738 (GTVn), recovering 79 % of that difference. Post-processed, MiniUNet3D matched nnU-Net v2 on GTVp Dice (p = 0.113) but remained inferior on nodal disease after Bonferroni correction (Dice p = 0.041; surface Dice p = 0.049). Catastrophic GTVp failures were 25/98 raw, 8/98 post-processed and 1/98 for nnU-Net v2 (McNemar p = 0.016). Inference took 34 s versus 78 s per case on the same GPU. Conclusions. Post-processing recovered most, but not all, of the difference between the two models, and it did not confer robustness: an eight-fold higher rate of empty contours on small primaries persisted, which is the more consequential difference for planning safety. Pipeline comparisons reported without a post-processing ablation risk attributing to a network what post-processing supplied.

Diffusion models achieve high reconstruction quality in low-dose computed tomography (LDCT), but their iterative sampling trajectories impose substantial computational costs. Unlike unconditional generation, paired LDCT reconstruction starts from an image that already contains the anatomy and spatial structure of the standard-dose CT (SDCT) target; reconstruction primarily requires correcting dose-related noise and artifacts. We therefore introduce Residual Endpoint Flow Matching (REFM), an LDCT reconstruction method that learns to transport an LDCT image directly toward its paired SDCT endpoint rather than defining a noise-to-image trajectory. REFM predicts the residual velocity along linear interpolations between both images and supports single-step and multi-step reconstruction using the same trained network. We evaluate five model capacities using 1 to 50 Euler steps against deterministic U-Net and diffusion-based baselines. Across all REFM variants, one-step inference consistently provides the highest reconstruction quality. On the TCIA validation set, REFM Base achieves 50.98 dB PSNR and 0.9865 SSIM at 94.54 fps, compared with 50.92 dB, 0.9847, and 9.26 fps for DDPM-10. REFM Small retains 50.71 dB while increasing throughput to 198.56 fps. Without fine-tuning, REFM Base also matches the 25-step DDPM baseline on the external Mayo Clinic dataset, although DDPM remains stronger on synthetically degraded CRLM images. Thus, our results show that exploiting paired anatomical correspondence enables diffusion-level LDCT reconstruction with a single step reconstruction.

Background. Extracellular volume fraction (ECV) derived from contrast-enhanced CT is a validated marker of hepatic fibrosis and has been reported to differ between hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma. In published work it is obtained from a small number of hand-placed two-dimensional regions of interest, and the software that computes it is either tied to one manufacturer's workstation or based on spectral or dual-energy acquisition. We are not aware of an accessible tool that produces voxelwise liver ECV maps from conventional single-energy multiphase CT. Methods. We developed CT ECV Mapper, a scripted 3D Slicer extension with a three-layer architecture whose numerical core imports neither slicer nor vtk and is unit-tested outside 3D Slicer. The interactive application provides two-stage registration that the operator inspects and accepts before any ECV is computed, operator-placed three-dimensional regions of interest, user-adjustable calculation parameters, a voxelwise ECV color map and ROI statistics; the same logic layer can be driven unattended across a cohort. The tool was applied to the 164 patients of the public WAW-TACE multiphase HCC/TACE dataset that have both unenhanced and delayed-phase series. Results. 156 of 164 cases (95.1%) completed unattended. Whole-liver ECV had a median of 36.2% (interquartile range 31.9-41.5), consistent with published CT-ECV values for fibrotic and cirrhotic liver. Registering the arterial and portal phases on demand extended tumor ECV from the 38 lesions a conventional two-phase pipeline can reach to 248 lesions in 156 patients. Every failure was attributable to an identifiable mechanism: craniocaudal field-of-view mismatch between phases in six cases, aortic calcification within the blood-pool region in one, and in one case a labeling error in the source dataset, in which the series declared as unenhanced proved to be a second reconstruction of the portal venous phase; this was detected by the blood-pool validity check rather than by visual review. Conclusions. Voxelwise CT ECV mapping of the liver and of hepatic tumors is feasible from conventional multiphase CT on an open platform, both interactively and as an unattended batch, with quality-control instrumentation that fails explicitly and diagnosably. This is a technical development and feasibility report; the application has not been evaluated against a reference standard and no claim of clinical validity is made.

Purpose: Attenuation correction (AC) of PET images is essential for accurate quantification. Brain PET studies comprising simultaneous EEG (PETEEG) may suffer from metal artifacts in CT images (CTEEG), or improper correction when electrodes are not present in the CT (CT0). As these influences are not well-characterized, we aim to compare metal artifact reduction (MAR) techniques for CTEEG images, and evaluate differences between attenuated-corrected PETEEG using CT0 and CTEEG with MAR, synthetically placed electrodes (CTEEG-synth) and extended Hounsfield unit (HU) range. Methods: 19 healthy participants underwent two total-body PET/CT scans with [18F]FDG, with and without 32 EEG scalp electrodes, respectively. We evaluated five MARs to reduce streaks caused by the EEG electrodes in the CTEEG. Finally, CT0, CTEEG with (CTEEG-iMAR-Ext) and without extended HU range (CTEEG-iMAR) and CTEEG-synth were used to perform attenuation correction of PETEEG. We compared our results to PET0/CT0 scan using relative differences. Results: CTEEG and CTEEG-iMAR showed the smallest differences to CT0. PETEEG/CTEEG-iMAR-Ext exhibited the lowest differences to PET0/CT0 (average bias across all regions of -0.46%), followed by similar performance of PETEEG/CTEEG-iMAR (-0.73%) and PETEEG/CTEEG (-0.76%). Conversely, PETEEG/CT0 demonstrated the largest average differences (-1.81%), with values reaching -2.71% in the parietal lobe. These differences were consistent across subjects, yielding significant effects in most of the brain (pFWE < 0.05). CTEEG-synth performed not as good as CTEEG (-1.21%). Conclusions: CTEEG with extended HU range is most suitable for attenuation correction of PETEEG images, with MAR correction offering little additional improvement.

Radiosensitizing nanoparticles represent a promising approach for enhancing the efficacy of proton radiotherapy; however, their performance is constrained by restricted penetration into tumor tissue, resulting in preferential perivascular accumulation. Here, we develop a spatially distributed mathematical model of a growing tumor undergoing proton therapy with intravenously administered radiosensitizing nanoparticles to investigate treatment optimization strategies. Using physiologically plausible parameter ranges informed by our own experimental measurements and published data, we demonstrate that co-administration of targeted nanoparticles with antibodies binding to the same tumor receptors can overcome transport-induced localization and promote a more uniform intratumoral redistribution of nanoparticles before irradiation. Population-level simulations across heterogeneous parameter sets suggest that moderate antibody doses consistently prolong tumor regrowth time, whereas higher antibody doses produce a pronounced and robust increase in tumor cure probability under a single high-dose irradiation regimen representative of preclinical settings. A key conceptual result of our analysis is the asymmetric risk associated with antibody co-administration. In contrast to antibody--drug conjugates, for which excessive dosing of unconjugated antibodies may severely compromise therapeutic efficacy, co-administration of antibodies with nanoparticle-based radiosensitizers constitutes a "safe-by-design" strategy with respect to tumor cell kill in the modeled single high-dose irradiation setting: although excessive antibody doses may yield suboptimal outcomes, they cannot reduce tumor cell kill below that achieved with targeted nanoparticles administered without antibodies. These findings identify antibody-mediated spatial redistribution of radiosensitizing nanoparticles as a favorable strategy that is expected to provide robust therapeutic benefit despite substantial variability in tumor characteristics.

Introduction Anatomical endoscopic enucleation of the prostate (AEEP) techniques, including bipolar enucleation (B-TUEP), holmium laser enucleation (HoLEP), thulium laser enucleation (ThuLEP), and thulium fibre laser enucleation (ThuFLEP), demonstrate comparable clinical outcomes for benign prostatic hyperplasia. As clinical equivalence is increasingly established, cost becomes a key determinant of modality selection. We performed a cost minimisation analysis comparing index procedural costs across AEEP modalities from an institutional perspective. Methods A cost minimisation model was developed from the institutional perspective, incorporating amortised capital costs, maintenance, and consumables. In addition to the base-case scenario of 180 cases per year, we modelled two additional case volume scenarios: low (50 cases/year) and high (500 cases/year) volume. Thu:YAG laser fibres were modelled on two scenarios: disposable single-use, and reusable fibres (up to 10 cases per fibre). Breakeven analysis determined the threshold volume at which each laser modality achieves cost parity with B-TUEP, and one-way sensitivity analysis was performed on key cost parameters. Analysis was limited to index procedural costs calculated in Singapore dollars. Results At the base case of 180 cases per year, B-TUEP had the lowest index procedure cost (SGD 1,018), followed by ThuFLEP (SGD 1,584), ThuLEP (1,599), and HoLEP (SGD 1,655). Breakeven analysis demonstrated that HoLEP, ThuLEP, and ThuFLEP can never achieve cost parity with B-TUEP when laser fibres are single-use, as laser modalities carry higher costs on both capital and per-case dimensions. ThuLEP with reusable fibres (10 uses per fibre) was the only modality to cross below B-TUEP, at a breakeven volume of 198 cases per year. At 500 cases per year with reusable fibres, ThuLEP achieved the lowest cost (SGD 847), representing a 15.4% saving over B-TUEP. Sensitivity analysis identified annual case volume and B-TUEP loop cost as the most influential parameters. Conclusion Index procedural costs in AEEP are strongly influenced by case volume and consumable strategy. While B-TUEP remains cost-efficient at low volume, high-volume practice combined with reusable Thu:YAG fibre technology enables cost parity and potential cost advantage for laser enucleation. These findings highlight the importance of economies of scale and device utilisation in technology adoption.

Background: Trophoblast cell surface antigen 2 (TROP2, encoded by TACSTD2) is a transmembrane glycoprotein overexpressed in multiple aggressive epithelial carcinomas. While antibody drug conjugates targeting TROP2 have achieved regulatory approvals, acquired payload resistance and systemic off-target toxicities limit sustained remissions. Radionuclide Drug Conjugates (RDCs) represent a potent alternative modality capable of delivering cytotoxic ionizing radiation directly to target cells. However, selecting the optimal therapeutic radioisotope between long-range beta emitters (177Lu) and short-range, high linear energy transfer (LET) alpha emitters (225Ac) under heterogeneous TROP2 spatial distributions remains an unaddressed clinical challenge. Methods: We developed an automated computational pathology and spatial microdosimetry pipeline to resolve microscopic TROP2 expression gradients and simulate absorbed radiation dose distributions from digitized whole-tissue immunohistochemistry (IHC) sections (N = 14). Optical density matrices were de-convoluted in Hematoxylin-Eosin-DAB (HED) color space to isolate the DAB chromogen. Continuous 2D spatial density distributions and topological surface profiles were reconstructed. Physical radiation energy deposition was modeled using radial dose point kernels for 177Lu (mean range ~670 m, LET 0.2 keV/m) and 225Ac (mean range ~65 m, LET 100 keV/m, 4 alpha particles per decay cascade). Therapeutic Index (TI, ratio of mean target to non-target absorbed dose), target coverage, and spatial specificity were quantified across all specimens. Results: Quantitative image deconvolution revealed that TROP2 expression across the cohort was characteristically focal and clustered, with a mean positive area fraction of 1.55 +/- 2.22% (range: 0.08% to 6.85%) and mean DAB signal intensity of 0.256 +/- 0.043. In all 14 evaluated specimens (100%), 225Ac-labeled RDCs demonstrated superior tumor-to-stroma dose localization compared to 177Lu-labeled RDCs. The cohort-wide mean Therapeutic Index was significantly higher for 225Ac (1.26 +/- 0.14) than for 177Lu (1.01 +/- 0.02, p < 0.0001, paired two-tailed t-test). Because the path length of 177Lu beta particles exceeded target cell nest dimensions by up to 30-fold, 177Lu suffered from severe off-target crossfire spillover into antigen-negative stroma. In contrast, 225Ac confined high-LET ionization tracks strictly within the micro-geographic boundaries of TROP2-expressing clusters. Conclusions: In tumors displaying focal or sparse TROP2 micro-architecture, Targeted Alpha Therapy with 225Ac-RDCs offers a superior biophysical profile over beta-emitting 177Lu-RDCs, maximizing cluster cell kill while sparing adjacent normal tissue stroma. This computational microdosimetry framework provides a practical tool to guide rational isotope pairing in RDC drug design.

Radiation oncology has a long history of developing in-house health information technology (HIT) tools such as quality assurance (QA) checklists, yet there is little guidance from professional bodies on how to implement these tools in complex clinical environments. Building on our previous work that used human-centered participatory co-design, the Task-User-Representation-Function (TURF) framework, and multi-method usability evaluations to design and develop an enhanced dosimetry QA checklist (DQC), this study investigated the barriers and facilitators (determinants) to implementing the enhanced DQC in a radiation oncology clinic, examined implementation strategies, proposed an implementation framework for QA checklists in radiation oncology, and assessed four implementation outcomes: acceptability, appropriateness, feasibility, and adoption. We conducted a qualitative implementation study using an abductive research approach at an academic medical center. All key stakeholders (dosimetrists, physicists, trainees, and software developers) participated in semi-structured interviews, field observations, and surveys across pre-implementation, implementation, and post-implementation phases. Data were analyzed using a hybrid inductive-deductive approach, with deductive coding guided by an adapted Consolidated Framework for Implementation Research (CFIR) mapped to the Unified Theory of Acceptance and Use of Technology and by the Expert Recommendations for Implementing Change (ERIC) compilation. We identified 4 CFIR constructs and 12 sub-constructs as barriers, with structural characteristics and planning showing the highest negative valence, and 5 CFIR constructs and 19 sub-constructs as facilitators, with relative advantage, culture, and leadership engagement showing the highest positive valence. Participants' suggestions mapped to 19 ERIC strategies in 7 clusters, and the CFIR-ERIC matching tool identified 14 evidence-based strategies in 4 clusters that informed a proposed phased implementation framework. Acceptability, appropriateness, and feasibility scores improved significantly from pre-implementation to implementation for all professional roles (p<0.05), yet adoption reached 100% only in the sixth week of implementation. These findings highlight the value of combining subjective and objective implementation outcomes and provide a practical, evidence-based framework for implementing in-house QA checklists in radiation oncology that warrants validation in diverse settings.

Herein, we assess the potential of low-dose stereotactic radiosurgery (SRS) to modulate neuronal network states without apparent damage to cellular integrity. Using a small animal radiation research platform (SARRP), a 1 mm3 focal target in the mouse visual cortex was irradiated with doses of 5, 20, and 40 Gy. One-month later a significant dose-dependent increase in excitatory synapse numbers was observed, notably limited to the treated visual cortex and not the adjacent somatosensory cortex. Six months post-irradiation, cortical neuronal microcircuit activity was monitored in awake mice using high sensitivity two-photon calcium imaging. A single 5 Gy dose resulted in a significant microcircuit-wide increase of spontaneous neuronal activity, consistent with a lasting shift in the functional architecture of the irradiated nodal network. At higher SRS doses (40 Gy) this neuromodulatory window appears to close. In aggregate, these data suggest that low-dose radiation could, in some circumstances, be exploited by selected high precision SRS technologies to durably modulate neuronal circuit disorders. Some, or even all the clinical benefits reported in the companion article by Zhao et al. are likely attributable to the biological properties we sought to characterize in our research. One Sentence SummaryLow-dose stereotactic radiosurgery effectively and durably modulates neuronal excitability via synaptic re-organization and could open new clinical possibilities for neuromodulation.

Automated lesion segmentation is increasingly central to PSMA PET/CT interpretation, supporting staging, treatment planning, and response assessment at a scale that outpaces available nuclear-medicine expertise. However, automated PSMA-PET/CT whole-body lesion segmentation models are trained on images alone, with no knowledge of where in the body prostate metastases actually tend to occur. Radiologists use clinical domain knowledge of metastatic spread, but its absence in machine learning models produces false positives in anatomically implausible locations and missed lesions in high-risk sites such as the liver. In this work, we explore whether population-level spatial knowledge of metastatic spread can be used to augment deep learning segmentation predictions, and how such a prior should be fused with a network's output, without additional training. We build a data-driven metastasis atlas from 375 expert-annotated whole-body PSMA PET/CT scans and investigate its fusion with a trained segmentation network under a Bayesian framework, in which prediction probabilities from an nnU-Net-based lesion segmentation model serve as the likelihood and the data-driven atlas as the prior. Because metastases occupy only a small fraction of whole-body voxels, the atlas's peak probability is too low, and standard power-scaled or naive Bayesian pooling references lack the tools to deal with this shortcoming. This causes these standard fusion strategies to fail and, in the naive Bayesian case, to sharply degrade performance. We instead derive a calibrated, background-referenced log-odds fusion, one of many possible approaches to combine a population atlas with a deep learning model's predictions, distinct from classical multi-atlas label fusion in that it fuses a single population prior with a trained network's softmax rather than combining several registered atlases. Furthermore, this approach is neutral outside atlas support by construction, reduces exactly to the baseline network when unweighted, and requires no retraining. This atlas fusion significantly improved mean Dice over the baseline nnU-Net on a disjoint internal test set ($+0.011$, Holm-adjusted $p=0.021$) and on an independent external cohort ($+0.0129$, Holm-adjusted $p=3.8\times10^{-16}$), with lesion sensitivity improving from 0.849 to 0.861 internally and Dice improving over baseline in every stratified anatomic region, including the rare, high-risk sites motivating this work, while naive Bayesian pooling degrades performance sharply and power-scaled pooling underperforms it throughout. Our findings suggest that population-level spatial priors can meaningfully augment deep learning predictions in whole-body oncologic segmentation, provided the fusion rule is calibrated to where the prior actually carries signal.

Formalin-fixed prostate tissue samples were imaged by propagation-based synchrotron phase contrast micro computed tomography ({micro}CT) with a 3D spatial resolution of ca. 3 {micro}m. Post-{micro}CT, samples were prepared for histology with sections close to coplanar with the transverse {micro}CT image planes. Haematoxylin and eosin stained sections were examined by an expert prostate histopathologist and compared qualitatively with corresponding {micro}CT-visible microstructure features. There is potential for {micro}CT to provide complimentary information to conventional histology and light microscopy without the need for preparation of stained thin sections. For the imaging conditions and spatial resolution of our study, {micro}CT may provide tissue architectural features similar to those used in Gleason grading, albeit without clear subcellular microstructure detail. At the spatial resolution of our study {micro}CT may provide novel 3D microstructure information for validation of diffusion weighted magnetic resonance imaging (MRI) methods. As an example, we demonstrate a qualitative correlation between {micro}CT-derived stromal fibre orientation and preferential water diffusion direction measured by diffusion tensor MRI microscopy of the same sample.

IntroductionTherapeutic ultrasound has been extensively studied in ablative and sonodynamic contexts, leaving the intrinsic bioactivity of continuous non-thermal low-intensity ultrasound (LIU) largely uncharacterized. ObjectivesTo characterize the tumor biological and immunomodulatory effects of non-thermal continuous LIU in complementary in vitro and in vivo breast cancer models, underpinned by a standardized exposure platform characterized through finite element simulations and experimental validation. MethodsAcoustic and thermal fields were characterized and optimized using in silico simulations and validated against hydrophone and temperature measurements to ensure homogeneous, non-thermal exposure (1MHz, 1W/cm2, 100% duty cycle). 4T07 murine mammary carcinoma spheroids received 20min LIU treatment, and metabolic activity, apoptosis, and intracellular stress-associated markers were assessed. In a syngeneic orthotopic 4T07 mammary carcinoma model in BALB/c mice, up to six LIU treatment cycles were administered; tumor growth, survival, histopathology, immunohistochemistry, bulk tumor RNA sequencing, spleen volume and plasma cytokine profiles were assessed. ResultsIn vitro and intratumoral temperatures remained within the physiological range ([&le;]39{degrees}C) throughout exposure. In spheroids, LIU reduced ATP content by more than 40% and significantly increased apoptotic, Hsp70 and Hsp90 cell fractions. In vivo, cyclic LIU slowed tumor growth, increased intratumoral necrosis, and significantly prolonged time to humane endpoint compared to untreated controls. LIU promoted early intratumoral myeloid cell infiltration and shifted the tumor transcriptome (2,573 differentially expressed genes), with enrichment in gene sets associated with immunogenic cell death, pattern-recognition, inflammatory, and innate and adaptive immune programs and downregulation of pro-tumorigenic pathways. LIU enriched the transcriptional signatures of M1 macrophage polarization and, notably, B-cell compartment engagement, which has not previously been reported for standalone continuous mechanical ultrasound. LIU significantly attenuated tumor-associated splenomegaly and elevated plasma IL-1, TNF-, and IL-10. ConclusionThese results establish a reproducible preclinical platform and provide a hypothesis-generating mechanistic basis for evaluating LIU as an adjunct to immune checkpoint blockade. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=124 SRC="FIGDIR/small/743931v1_ufig1.gif" ALT="Figure 1"> View larger version (49K): org.highwire.dtl.DTLVardef@31d366org.highwire.dtl.DTLVardef@12df6aborg.highwire.dtl.DTLVardef@9d91adorg.highwire.dtl.DTLVardef@c72b8a_HPS_FORMAT_FIGEXP M_FIG C_FIG

Despite the well-known health risks of neutron exposures, key gaps remain in understanding neutron-induced molecular responses and identifying reliable biodosimetric markers that distinguish neutrons from photon exposure. We provide the first genome-wide analysis of the human blood transcriptional response to an accelerator-derived fission-like spectrum of neutrons versus photons, evaluating transcriptomic relative biological effectiveness (RBE) and radiation quality-discriminating gene signatures. Whole blood from healthy donors was irradiated ex vivo with X-rays (140 kV, 0-4 Gy, n = 3) or neutrons (0.1-8 MeV, 0-1 Gy, n = 2), incubated for 6 h or 24 h, and processed for RNA sequencing from peripheral blood mononuclear cells (PBMCs). Neutrons were markedly more potent than X-rays at inducing differentially expressed genes (DEGs) at equal doses, showing a peak response 6 h post-irradiation followed by a decline. In contrast, X-rays caused a continuous increase in DEGs up to 24 h (neutrons vs. X-rays at 1 Gy: 1,449 vs. 121 DEGs at 6 h; 996 vs. 621 DEGs at 24 h). A universal p53-centered 34-gene signature, including FDXR, EDA2R, GADD45A, and ZMAT3, showed highly monotonic dose responses (Spearman correlation coefficient {approx} 1) across donors, radiation qualities, and timepoints. Additionally, difference-in-differences analysis identified radiation quality-discriminating genes only at 6 h, with transcriptional convergence observed by 24 h, suggesting a very narrow time window for biodosimetric differentiation. We identified a neutron-specific gene signature driven by cGAS-STING-NF-{kappa}B signaling (RELB, NFKB1, C3, MALAT1) and suppression of B-cell and myeloid identity genes (IGHD, TCL1A, CLEC7A, TLR2), defining a biologically coherent neutron quality index with distinct immunomodulatory effects. For the first time, we assessed neutron RBEs at the gene, pathway, and global transcriptomic levels in a human blood model, reporting a global transcriptomic neutron RBE of 1.30 (95% CI: 1.14-1.49) at 6 h and 1.21 (95% CI: 1.14-1.28) at 24 h, providing a valuable basis for biodosimetry in mixed-field exposure scenarios. Our findings advance the mechanistic understanding of neutron radiation responses and support the development of biodosimetric approaches for mixed-field exposure scenarios.

Rationale: Neuroblastoma is a devastating pediatric malignancy, for which surgical resection is a key factor in long-term survival. However, there are significant challenges in its resection, particularly in high-risk disease, as neuroblastoma encases surrounding critical structures, is often difficult to distinguish from desmoplastic or scar tissue, and can carry occult deposits of disease not readily identified on preoperative imaging or intraoperative visualization. Building on the principles of fluorescent and radio-guided surgery, in combination with the known overexpression of GD2 in neuroblastoma, we sought to develop and optimize 111In-Dinutuximab-IRDye800, a dual-modality GD2-targeted intraoperative molecular imaging agent, for use in pediatric neuroblastoma to help enhance patient safety while facilitating a more complete resection. Methods: Dinutuximab was conjugated to IRDye800 and DTPA, then radiolabeled with Indium-111 to yield 111In-Dinutuximab-IRDye800. Optimization occurred through ELISA assay to assess binding affinity, fluorescence intensity analysis to determine the optimal fluorescent degree of labeling, and phototoxicity testing through flow cytometry. Rodent models of neuroblastoma were then generated through injection of SK-N-BE(2) human neuroblastoma cells into the left adrenal glands of nude mice or RNU rats. A series of fluorescent and gamma biodistributions was performed, varying the dose, timing, and specific activity of the tracer. Tumor and organ uptake of the tracer was compared with one- or two-way ANOVA as appropriate, with Sidaks multiple comparison test to compare tumor uptake to individual organs. Once optimization was complete, a clinically significant events study modeled after human clinical trials was performed to evaluate the in vivo capabilities of 111In-Dinutuximab-IRDye800. Results: Increased ratios of IRDye800 per antibody led to decreased binding affinity for GD2 and was associated with formulation instability without significant return on fluorescence intensity. Specific activity of the tracer was not found to impact overall biodistribution of the tracer. A 45-50 microgram dose of 111In-Dinutuximab-IRDye800 with ratios around 1 DTPA and 1-1.5 IRDye800 per antibody imaged 4 days after tracer administration was found to be the optimal combination that maximized detectable tumor-specific signal. In the clinically significant events study mirroring human IMI clinical trials, fluorescent guidance identified additional malignant lesions not originally detected under white light in 64% of rodents. Conclusions: 111In-Dinutuximab-IRDye800 is a dual-modality GD2-targeted intraoperative imaging agent that is well-poised for clinical translation. As it preserves tumor specificity, yields clinically meaningful radiofluorescent signal, and is well-tolerated without adverse events after optimization was completed, it carries the potential to positively impact the safety and completeness of neuroblastoma resection.

Tumors consist of heterogeneous phenotypic cells, such as normoxic cells, which are highly proliferative, and hypoxic cells, which are less proliferative. Their phenotypic switching depends on tumor microenvironmental factors, such as oxygen and nutrient concentrations supplied by local blood vessels. However, during ongoing angiogenesis, the process of sprouting new blood vessels at the tumor site from pre-existing blood vessels, and how this phenotypic switching affects and impacts tumor growth, remains poorly understood. In this article, we formulate a mathematical model to elucidate the crosstalk between vasculature and tumor cellular heterogeneity during tumor progression. The model results show a strong agreement with the experimental data. Our simulation results demonstrate that ongoing angiogenesis increases tumor growth rate. In addition, we observe that the influence of hypoxic cells on phenotypic switching from normoxic to hypoxic is more pronounced than their influence on the transition from hypoxic to normoxic. Furthermore, we perform a global sensitivity analysis using the Sobol's method to assess the importance of the model's parameters. It highlights that the volume at which blood vessels attain half-maximal rate has the maximum effect on the model.